**Author details**

*Translational Research in Cancer*

**3. Conclusion**

against CSCs.

**Abbreviations**

We then evaluated the subacute toxicity after 29 days of intraperitoneal treatment with 100 mg/kg twice a week. Bozepinib-treated mice presented no weight loss or unusual behaviour, and the histopathologic examination did not find any detectable toxicity in the liver or kidneys. These data indicate that, at the concentra-

Although we show promising data proving the efficacy of bozepinib over CSCs,

the mechanism by which bozepinib inhibits the CSC growth requires further detailed investigation. Moreover, the in vivo antitumor and anti-metastatic effect and the non-systemic toxicity of bozepinib encourage further studies on the therapeutic potential of this synthetic compound in breast and colon cancer patients. The detection of CSCs in multiple solid tumors over the past years represents a paradigm shift in oncology and will probably change our understanding of the tumourigenic process. The impressive number of publications that have appeared in

this field in recent years bears testimony to its enormous current interest.

ALDH aldehyde dehydrogenase activity

HMDS 1,1,1,3,3,3-hexamethyldisilazane

TBAF tetra-*n*-butylammonium fluoride

VEGF vascular endothelial growth factor

CSCs cancer stem cells

5-FU 5-fluorouracil Hh Hedgehog

PKR protein kinase R

TEA triethylamine THF tetrahydrofuran TI therapeutic index TMSCl trimethylsilyl chloride

DEAD diethyl azodicarboxylate DIAD diisopropyl azodicarboxylate FACS fluorescence-activated cell sorter

We expect this chapter to stimulate fresh activity within the medicinal chemistry community and to result in the enlargement of chemical structures active

tion used, bozepinib did not cause any systemic damage [30].

**136**

Joaquín M. Campos1,2\*, Ana Conejo-García1,2 and Olga Cruz-López1,2

1 Department of Pharmaceutical and Organic Chemistry, Faculty of Pharmacy, University of Granada, Granada, Spain

2 Granada Biosanitary Institute (ibs. GRANADA), Andalusian Health Service, University of Granada, Granada, Spain

\*Address all correspondence to: jmcampos@ugr.es

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
